ELUT Stock Price Chart
ELUT Earnings
Elutia Inc
$1.01
1.12%
$0.01
At close: May 08, 16:00:00 GMT-4
$1.01
0%
$0
Post-market: May 08, 20:00:00 GMT-4
Back
Elutia Inc (ELUT) Earnings
Latest Earnings Results: Q4 '25
Reported: 2026-03-11
Historical Earnings
Quarterly
Annual
EPS
Revenue
Earnings FAQ
How did ELUT's recent EPS compare to expectations?
How did Elutia Inc ELUT's revenue perform in the last quarter?
What is the revenue estimate for Elutia Inc?
What's the earning quality score for Elutia Inc?
When does Elutia Inc report earnings?
What are Elutia Inc's expected earnings?
Did Elutia Inc beat earnings expectations?
Key Stats
Prev.Close
$0.9988
Open
$1.05
Day's Range
$0.9902 - $1.05
52 week range
$0.5 - $2.64
Volume
129.4K
Avg.Volume
216.2K
Dividend yield
--
EPS (TTM)
1.23
Market Cap
$43.2M
What is ELUT?
Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. The company is headquartered in Silver Spring, Maryland and currently employs 51 full-time employees. The company went IPO on 2020-10-08. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
